Attached files
| file | filename |
|---|---|
| EX-23.1 - EX-23.1 - Eledon Pharmaceuticals, Inc. | d899630dex231.htm |
| EX-5.1 - EX-5.1 - Eledon Pharmaceuticals, Inc. | d899630dex51.htm |
| S-1 - S-1 - Eledon Pharmaceuticals, Inc. | d899630ds1.htm |
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated March 27, 2019, in the Registration Statement (Form S-1) and related Prospectus of Novus Therapeutics, Inc. for the registration of 7,243,135 shares of its common stock.
/s/ Ernst & Young LLP
Irvine, California
March 25, 2020